[
    "{\"step_by_step_thinking\": \"Teplizumab is a monoclonal antibody that targets the CD3 receptor on T cells. It has been studied for its potential in preventing type 1 diabetes in individuals at high risk. Clinical trials have shown that teplizumab can delay the onset of clinical diabetes in individuals with autoantibodies associated with type 1 diabetes. These trials have demonstrated promising results in terms of preserving beta cell function and reducing the need for exogenous insulin. Therefore, based on the available evidence, teplizumab does hold promise for diabetes prevention.\", \"answer_choice\": \"A\"}"
]